Investing.com - Pasithea Therapeutics reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Pasithea Therapeutics announced earnings per share of $-0.17 on revenue of $218.6K. Analysts polled by Investing.com anticipated EPS of $-0.14 on revenue of $100K.
Pasithea Therapeutics shares are down 42% from the beginning of the year , still down 81.87% from its 52 week high of $5.57 set on Monday, November 29, 2021.
Pasithea Therapeutics follows other major Healthcare sector earnings this month
Pasithea Therapeutics's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar